Space infrastructure company Redwire Corporation (NYSE: RDW) on Wednesday announced a collaboration with biopharmaceutical company Bristol Myers Squibb (BMS) to study small molecule drug compounds aboard the International Space Station (ISS).

Utilising Redwire's PIL-BOX pharmaceutical development platform, this mission aims to enhance drug stability, streamline manufacturing, and improve efficiencies across oncology, immunology, and cardiovascular therapies.

In addition, Redwire is launching another PIL-BOX investigation with ExesaLibero Pharma, targeting ELP-004, a drug that addresses excess bone removal linked to conditions like rheumatoid arthritis, multiple myeloma and certain cancers. This mission will support the development of advanced treatments for bone diseases.

A third experiment, conducted with Butler University, seeks to produce high-quality seed crystals in microgravity, potentially advancing pharmaceutical production on Earth. This is Butler's second investigation using PIL-BOX.

Redwire has launched 16 PIL-BOX missions to date, with 12 more scheduled aboard the upcoming SpaceX-31 cargo resupply flight to the ISS. The company aims to drive breakthroughs in drug development and other advanced technologies with significant commercial potential through its space-based research initiatives.